Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 864 clinical trials
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12)

This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2

paclitaxel
bone scan
neutrophil count
immunohistochemistry
doxorubicin
  • 8 views
  • 20 Jun, 2022
  • 43 locations
ARX788 in Breast Cancer With Low Expression of HER2

A Phase 2 Study of ARX788 in unresectable and/or metastatic breast cancer with low expression of HER2.

  • 0 views
  • 15 May, 2022
  • 1 location
Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer

This is a one-arm, single site, open-label phase II study. Patients will be enrolled in the screening step at the start of the second line of chemotherapy, and will undergo blood draws for ctDNA detection. Patients for whom ctDNA was successfully detected and found informative by the study executive board …

  • 0 views
  • 30 Oct, 2021
  • 1 location
Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

This is a multicenter, phase II, open-label, single-arm investigator initiated trial to evaluate the efficacy and safety of eribulin mesylate combined with anlotinib in metastatic HER2 negative

  • 3 views
  • 29 May, 2021
  • 1 location
ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases

A Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose Disease is resistant or refractory to Tyrosine kinase inhibitors (TKI).

  • 1 views
  • 19 Jun, 2022
  • 1 location
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors

  • 0 views
  • 15 Mar, 2022
  • 1 location
Research for the Molecular Imaging of the HER2 Targeting Tracer

To use the molecular PET radionuclide (Ga-68 or F-18) labelled HER2 Affibody to detect the expression of HER2 in the primary and metastatic lesions in patients with HER2 positive or suspicious

  • 0 views
  • 04 Oct, 2022
  • 1 location
  • 0 views
  • 24 Apr, 2022
  • 1 location
Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

90 patients with HER2 negative breast cancer will be randomised to receive 18 weeks of chemotherapy treatment, either 6 cycles of 3 weekly Cabazitaxel or 6 cycles of weekly Paclitaxel to

  • 263 views
  • 23 Jan, 2021
  • 12 locations
PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

The purpose of this study is to assess the safety and effectiveness of PD-1 Combined With Pyrotinib for First-line chemotherapy failed HER2 Insertion Mutation Positive Advanced Non-small Cell

  • 1 views
  • 12 Mar, 2022
  • 1 location